ClinicalTrials.gg
CompletedNCT01624259AWARD-6Updated Oct 9, 2014Results posted

A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes

A Phase 3 interventional study of LY2189265 and Liraglutide in Type 2 Diabetes, sponsored by Eli Lilly and Company. Completed at 57 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-09.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
599
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.

Enrollment
13th of 54
599 · median 159
Started
2012
with 7 others
Phase 3
22 of 54
1 open now
Registered
24th of 54
by date
Lead sponsor
43 of 54
Eli Lilly and Company

Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 13th largest by enrollment, is one of 8 that started in 2012, is one of 22 in phase 3, and was the 24th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About dulaglutide

dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of the study is to assess the benefits and risks of once-weekly dulaglutide compared to once-daily liraglutide in participants with type 2 diabetes who have inadequate glycemic control on metformin.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes
  • Not optimally controlled on diet and exercise and a dose of metformin that is at least 1500 milligrams/day (mg/day) and has been at a stable dose for at least 3 months prior to the first study visit
  • Glycosylated () greater than or equal to 7.0% and less than or equal to 10.0%
  • Accept continued treatment with metformin throughout the trial, as required per protocol
  • Men and nonpregnant women aged greater than or equal to 18 years
  • Stable weight (plus or minus 5%) greater than or equal to 3 months prior to screening
  • (BMI) less than or equal to 45 kilograms/square meter (kg/m\^2)

Exclusion criteria

Exclusion Criteria:

  • Have type 1 diabetes mellitus
  • Have been treated with ANY other antihyperglycemic medications (other than metformin) at the time of the first study visit or within the 3 months prior to the first study visit
  • Have used insulin therapy (outside of pregnancy) any time in the past 2 years, except for short-term treatment of acute conditions, and up to a maximum of 4 weeks; any insulin use within 3 months prior to the first study visit
  • Have been treated with drugs that promote weight loss within 3 months of the first study visit
  • Are receiving chronic (greater than 14 days) systemic therapy or have received such therapy within the 4 weeks immediately prior to the first study visit
  • Have had any of the following cardiovascular conditions within 2 months prior to the first study visit: acute myocardial infarction, Class III or Class IV heart failure, or cerebrovascular accident
  • Have a known gastric emptying abnormality (such as, severe diabetic gastroparesis or gastric outlet obstruction) or have undergone gastric bypass (bariatric) surgery or restrictive bariatric surgery
  • Have acute or chronic hepatitis, signs and symptoms of any other liver disease, or level greater than or equal to 3 times the
  • Have a history of chronic pancreatitis or acute idiopathic pancreatitis or were diagnosed with any type of acute pancreatitis within the 3 month period prior to the first study visit
  • Have a serum creatinine greater than or equal to 1.5 milligrams/deciliter (mg/dL) (male) or greater than or equal to 1.4 mg/dL (female), or a less than 60 milliliters/minute (mL/minute)
  • Have any self or family history of type 2A or type 2B multiple endocrine neoplasia (MEN 2A or 2B, respectively) in the absence of known C-cell hyperplasia (this exclusion includes those participants with a family history of MEN 2A or 2B whose family history for the syndrome is Rearranged during Transfection (RET) negative; the only exception for this exclusion will be for participants whose family members with MEN 2A or 2B have a known RET mutation and the potential participant for the study is negative for that RET mutation)
  • Have any self or family history of medullary C-cell hyperplasia, focal hyperplasia, or carcinoma (including sporadic, familial, or part of MEN 2A or 2B syndrome)
  • Have a serum calcitonin greater than or equal to 20 picograms/milliliter (pg/mL)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
599 participants (actual)

Study arms

  • Experimental
    1.5 mg LY2189265

    LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 26 weeks Metformin: at least 1500 mg/day, oral, for 26 weeks

    Drug: LY2189265 · Drug: Metformin

  • Active comparator
    Liraglutide

    Liraglutide 0.6 mg, SC, once daily for 7 days, then titrated up to Liraglutide 1.2 mg, SC, once daily for 7 days, then titrated up to Liraglutide 1.8 mg, SC, once daily for 24 weeks Metformin: at least 1500 mg/day, oral, for 26 weeks

    Drug: Liraglutide · Drug: Metformin

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)

    Least Squares (LS) means of the glycosylated hemoglobin A1c (HbA1c) change from baseline to the primary endpoint at Week 26 was adjusted by fixed effects of treatment, country, visit, treatment-by-visit interaction, participant as random effect, and baseline HbA1c as covariates, via a mixed-effects model for repeated measures (MMRM) analysis using restricted maximum likelihood (REML).

    Time frame: Baseline, 26 Weeks

Secondary outcomes

  1. Change From Baseline in Body Weight at 26 Weeks

    LS means of the weight change from baseline to primary endpoint at Week 26 were calculated using analysis of covariance (ANCOVA) with HbA1c Strata, country, and treatment as fixed effects and baseline body weight as a covariate.

    Time frame: Baseline, Up to 26 Weeks

  2. Change From Baseline in Body Mass Index (BMI) at 26 Weeks

    BMI is an estimate of body fat based on body weight divided by height squared. LS means of the BMI change from baseline to primary endpoint at Week 26 were calculated using ANCOVA with HbA1c Strata, country, and treatment as fixed effects and baseline BMI as a covariate.

    Time frame: Baseline, Up to 26 Weeks

  3. Change From Baseline in Fasting Plasma Glucose (FPG) at 26 Weeks

    LS means of the FPG from baseline to primary endpoint at Week 26 were adjusted by fixed effects of treatment, country, baseline HbA1c strata, and baseline FPG as covariates, via ANCOVA with LOCF.

    Time frame: Baseline, Up to 26 Weeks

  4. Change From Baseline in 7-Point Self Monitored Plasma Glucose (SMPG) at 26 Weeks

    The SMPG data were collected at the following 7 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening meal; 2 hours post-evening meal; and bedtime. The mean of the 7 time points (Daily Mean) was also calculated. LS means of the SMPG change from baseline to primary endpoint at Week 26 were adjusted by fixed effects of treatment, HbA1c strata, country, visit, treatment-by-visit interaction, participant as random effect and baseline SMPG as a covariate, via a MMRM analysis using REML.

    Time frame: Baseline, 26 Weeks

  5. Percentage of Participants Achieving a Glycosylated Hemoglobin (HbA1c) ≤6.5% or <7% at 26 Weeks

    The percentage of participants who achieved the target HbA1c values at the primary endpoint were analyzed with a repeated logistic regression model (the generalized estimation equation \[GEE\] model). The model includes pooled country, treatment, visit, treatment-by-visit interaction, and baseline HbA1c as continuous covariates.

    Time frame: Up to 26 Weeks

  6. Change From Baseline in Homeostasis Model Assessment 2 Steady-state Beta (β)- Cell Function (HOMA2-%B) at 26 Weeks

    The homeostatic model assessment (HOMA) quantifies insulin resistance and beta-cell function. HOMA2-%B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady-state beta cell function (%B) as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100%. LS means of the HOMA2-%B change from baseline to primary endpoint at Week 26 was adjusted by fixed effects of treatment, country, baseline HbA1c strata, and baseline HOMA2-%B value as covariate, via an ANCOVA analysis using LOCF.

    Time frame: Baseline, Up to 26 Weeks

  7. Number of Participants With Reported and Adjudicated Cardiovascular Events

    Deaths and nonfatal cardiovascular (CV) adverse events (AEs) were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal CV AEs to be adjudicated include myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. The number of participants with reported CV events, number of participants with nonfatal CV events confirmed by adjudication, and number of deaths confirmed by adjudication are summarized cumulatively at 26 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline up to 26 Weeks

  8. Change From Baseline in Electrocardiogram (ECG) Parameters, Heart Rate (HR) at 26 Weeks

    ECG HR was measured. LS means of change from baseline were analyzed using ANCOVA with HbA1c strata, country, and treatment as fixed effects and baseline HR as a covariate.

    Time frame: Baseline, Up to 26 Weeks

  9. Change From Baseline in Electrocardiogram (ECG) Parameters PR and QTcF (Fridericia's) Intervals at 26 Weeks

    The QT interval is a measure of the time between the start of the Q wave and the end of the T wave. QTcF is the measure of the time between the start of the Q wave and the end of the T wave adjusted using Fridericia's formula. PR is the interval between the P wave and the QRS complex. These parameters were calculated from electrocardiogram (ECG) data. LS means of change from baseline for the PR and QTcF intervals will be analyzed using the MMRM similar to MMRM model for primary outcome, using corresponding baseline and HbA1c strata. Only ECGs obtained at scheduled visits will be used in these summaries and analyses.

    Time frame: Baseline, 26 Weeks

  10. Change From Baseline in Heart Rate (HR) at 26 Weeks

    Descriptive statistics for the actual measurements and LS means of change from baseline for HR (sitting) by treatment arm were analyzed using the MMRM model with treatment, country, visit, and treatment-by-visit interaction as fixed effects, baseline rate as a covariate, and participant as a random effect.

    Time frame: Baseline, 26 Weeks

  11. Change From Baseline in Blood Pressure (BP) at 26 Weeks

    Descriptive statistics for the actual measurements and change from baseline for sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured. LS means of change from baseline were calculated using MMRM with treatment, country, visit, and treatment-by-visit interaction as fixed effects, baseline BP as a covariate, and participant as a random effect.

    Time frame: Baseline, 26 Weeks

  12. Number of Participants With Adjudicated Acute Pancreatitis Events

    The number of participants with events of pancreatitis confirmed by adjudication were summarized cumulatively at 26 weeks (including a 30-day follow up). Pancreatitis events were adjudicated by a committee of physicians external to the Sponsor. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline up to 30 Weeks

  13. Change From Baseline in Calcitonin at 26 Weeks

    A summary of participants having changes in calcitonin values from baseline to primary endpoint of 26 weeks is presented.

    Time frame: Baseline, Up to 26 Weeks

  14. Change From Baseline in Lipase at 26 Weeks

    A summary of participants having changes in lipase evaluation from baseline to primary endpoint of 26 weeks is presented.

    Time frame: Baseline, Up to 26 Weeks

  15. Change From Baseline in Amylase at 26 Weeks

    A summary of participants having changes in amylase evaluation from baseline to primary endpoint of 26 weeks is presented.

    Time frame: Baseline, Up to 26 Weeks

  16. Percentage of Participants With Self-Reported Hypoglycemia Events

    Hypoglycemic events (HE) were classified as severe (episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (any time a participant felt that he/she was experiencing symptoms and/or signs associated with hypoglycemia and had a plasma glucose \[PG\] concentration of ≤70 mg/dL), asymptomatic (events not accompanied by typical symptoms of hypoglycemia but with a measured PG of ≤ 70 mg/dL), nocturnal (events that occurred between bedtime and waking), or probable symptomatic (events during which symptoms of hypoglycemia were not accompanied by a PG determination but that was presumably caused by a PG of ≤70 mg/dL). A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 26 Weeks

  17. Percentage of Participants Requiring Additional Intervention for Severe, Persistent Hyperglycemia

    An additional intervention (rescue therapy) was defined as any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation.

    Time frame: Baseline through 26 Weeks

  18. Rate of Hypoglycemic Events Adjusted Per 30 Days

    HE were classified as severe (episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (any time a participant felt that he/she was experiencing symptoms and/or signs associated with hypoglycemia and had a PG concentration of ≤70 mg/dL), asymptomatic (events not accompanied by typical symptoms of hypoglycemia but with a measured PG of ≤ 70 mg/dL), nocturnal (events that occurred between bedtime and waking), or probable symptomatic (events during which symptoms of hypoglycemia were not accompanied by a PG determination but that was presumably caused by a PG of ≤70 mg/dL). The hypoglycemia rate per 30 days was calculated by the number of hypoglycemia events within the period/number of days participant at risk within the period\*30 days. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 26 Weeks

  19. Time to Initiation of Additional Intervention for Severe, Persistent Hyperglycemia

    An additional intervention (rescue therapy) was defined as any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation. Participants who had no rescue therapy within specified study period were considered as censored observations at the last available contact date up to specified study period.

    Time frame: Baseline through 26 Weeks

  20. Number of Participants With Allergic or Hypersensitivity Reactions

    Allergic and hypersensitivity reactions that were considered possibly related to study drug by the investigator are presented. Serious and all other non-serious adverse events regardless of causality are summarized in the Reported Adverse Events module.

    Time frame: Baseline through 26 Weeks

  21. Number of Participants With Treatment Emergent LY2189265 Antibodies up to 26 Weeks and 4 Weeks After Last Dose

    LY2189265 (dulaglutide) anti-drug antibodies (ADA) were assessed at baseline, 26 weeks, and at the safety follow-up visit 4 weeks after study drug discontinuation in dulaglutide-treated participants. A participant was considered to have treatment emergent LY2189265 ADA if the participant had at least 1 titer that was treatment-emergent relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement. The number of participants with treatment-emergent LY2189265 ADA from postbaseline to follow up were summarized.

    Time frame: Baseline up to 4 Weeks Post Last Dose of Study Drug

  22. Percent Change From Baseline in Lipid Parameters at 26 Weeks

    A summary of percent change in lipid parameters (total cholesterol, high-density lipoprotein cholesterol \[HDL-C\], low density lipoprotein cholesterol \[LDL-C\], very low-density lipoprotein cholesterol \[VLDL\], and triglycerides) from baseline to primary endpoint of 26 weeks is presented. LS means of the lipid parameter from baseline to primary endpoint at Week 26 were adjusted by fixed effects of treatment, country, baseline HbA1c strata, and lipid parameter baseline as covariates, via ANCOVA with LOCF.

    Time frame: Baseline, Up to 26 Weeks

07

Results

Posted Oct 9, 2014

Participant flow

Participant flow — Overall Study
MilestoneLY2189265Liraglutide
Started299300
Received at least one dose of study drug299300
Completed269269
Not completed3031
Withdrew: Adverse event1818
Withdrew: Protocol violation12
Withdrew: Withdrawal by subject57
Withdrew: Physician decision11
Withdrew: Lost to follow-up23
Withdrew: Abnormal laboratory measure30

Outcome measures

PrimaryChange From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)

Least Squares (LS) means of the glycosylated hemoglobin A1c (HbA1c) change from baseline to the primary endpoint at Week 26 was adjusted by fixed effects of treatment, country, visit, treatment-by-visit interaction, participant as random effect, and baseline HbA1c as covariates, via a mixed-effects model for repeated measures (MMRM) analysis using restricted maximum likelihood (REML).

Time frame:
Baseline, 26 Weeks
Reported as:
Least squares mean · percentage of glycosylated hemoglobin
Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)
percentage of glycosylated hemoglobin1.5 mg LY21892651.8 mg Liraglutide
Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)-1.42 ± 0.05-1.36 ± 0.05
Statistical analysis
  • 1.5 mg LY2189265 vs 1.8 mg Liraglutide · Mixed Models Analysis · p = <0.001 (1-sided raw p-value (no multiplicity adjustment).) · Ls mean difference: -0.06 · 95% CI -0.19 to 0.07
  • 1.5 mg LY2189265 vs 1.8 mg Liraglutide · Mixed Models Analysis · p = 0.186 (1-sided raw p-value (no multiplicity adjustment)) · Ls mean difference: -0.06 · 95% CI -0.19 to 0.07
SecondaryChange From Baseline in Body Weight at 26 Weeks

LS means of the weight change from baseline to primary endpoint at Week 26 were calculated using analysis of covariance (ANCOVA) with HbA1c Strata, country, and treatment as fixed effects and baseline body weight as a covariate.

Time frame:
Baseline, Up to 26 Weeks
Reported as:
Least squares mean · kilograms (kg)
Change From Baseline in Body Weight at 26 Weeks
kilograms (kg)1.5 mg LY21892651.8 mg Liraglutide
Change From Baseline in Body Weight at 26 Weeks-2.90 ± 0.22-3.61 ± 0.22
Statistical analysis
  • 1.5 mg LY2189265 vs 1.8 mg Liraglutide · ANCOVA · p = 0.010 (No adjustment for multiplicity.) · Ls mean difference: 0.71 · 95% CI 0.17 to 1.26
SecondaryChange From Baseline in Body Mass Index (BMI) at 26 Weeks

BMI is an estimate of body fat based on body weight divided by height squared. LS means of the BMI change from baseline to primary endpoint at Week 26 were calculated using ANCOVA with HbA1c Strata, country, and treatment as fixed effects and baseline BMI as a covariate.

Time frame:
Baseline, Up to 26 Weeks
Reported as:
Least squares mean · kilograms/square meter (kg/m^2)
Change From Baseline in Body Mass Index (BMI) at 26 Weeks
kilograms/square meter (kg/m^2)1.5 mg LY21892651.8 mg Liraglutide
Change From Baseline in Body Mass Index (BMI) at 26 Weeks-1.05 ± 0.08-1.30 ± 0.08
Statistical analysis
  • 1.5 mg LY2189265 vs 1.8 mg Liraglutide · ANCOVA · p = 0.013 (No adjustment for multiplicity.) · Ls mean difference: 0.25 · 95% CI 0.05 to 0.45
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) at 26 Weeks

LS means of the FPG from baseline to primary endpoint at Week 26 were adjusted by fixed effects of treatment, country, baseline HbA1c strata, and baseline FPG as covariates, via ANCOVA with LOCF.

Time frame:
Baseline, Up to 26 Weeks
Reported as:
Least squares mean · milligrams/deciliter (mg/dL)
Change From Baseline in Fasting Plasma Glucose (FPG) at 26 Weeks
milligrams/deciliter (mg/dL)1.5 mg LY21892651.8 mg Liraglutide
Change From Baseline in Fasting Plasma Glucose (FPG) at 26 Weeks-34.81 ± 2.13-34.25 ± 2.11
Statistical analysis
  • 1.5 mg LY2189265 vs 1.8 mg Liraglutide · ANCOVA · p = 0.828 (No adjustment for multiplicity.) · Ls mean difference: -0.57 · 95% CI -5.69 to 4.56
SecondaryChange From Baseline in 7-Point Self Monitored Plasma Glucose (SMPG) at 26 Weeks

The SMPG data were collected at the following 7 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening meal; 2 hours post-evening meal; and bedtime. The mean of the 7 time points (Daily Mean) was also calculated. LS means of the SMPG change from baseline to primary endpoint at Week 26 were adjusted by fixed effects of treatment, HbA1c strata, country, visit, treatment-by-visit interaction, participant as random effect and baseline SMPG as a covariate, via a MMRM analysis using REML.

Time frame:
Baseline, 26 Weeks
Reported as:
Least squares mean · mg/dL
Change From Baseline in 7-Point Self Monitored Plasma Glucose (SMPG) at 26 Weeks
mg/dL1.5 mg LY21892651.8 mg Liraglutide
Change From Baseline in 7-Point Self Monitored Plasma Glucose (SMPG) at 26 Weeks-40.76 ± 1.50-38.51 ± 1.45
Statistical analysis
  • 1.5 mg LY2189265 vs 1.8 mg Liraglutide · Mixed Models Analysis · p = 0.228 (No adjustment for multiplicity.) · Ls mean difference: -2.25 · 95% CI -5.91 to 1.41P-value from pairwise comparison of LS means at 26 weeks from REML-based MMRM.
SecondaryPercentage of Participants Achieving a Glycosylated Hemoglobin (HbA1c) ≤6.5% or <7% at 26 Weeks

The percentage of participants who achieved the target HbA1c values at the primary endpoint were analyzed with a repeated logistic regression model (the generalized estimation equation \[GEE\] model). The model includes pooled country, treatment, visit, treatment-by-visit interaction, and baseline HbA1c as continuous covariates.

Time frame:
Up to 26 Weeks
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Glycosylated Hemoglobin (HbA1c) ≤6.5% or <7% at 26 Weeks
percentage of participants1.5 mg LY21892651.8 mg Liraglutide
HbA1c levels ≤6.5%54.650.9
HbA1c levels <7.0%68.367.9
Statistical analysis
  • 1.5 mg LY2189265 vs 1.8 mg Liraglutide · Regression, Logistic · p = 0.322 (P-value of treatment comparison at Week 26 is from repeated generalized linear mixed model (GLM model).) · Odds ratio (or): 1.23 · 95% CI 0.81 to 1.86No adjustment for multiplicity.
  • 1.5 mg LY2189265 vs 1.8 mg Liraglutide · Regression, Logistic · p = 0.925 (No adjustment for multiplicity.) · Odds ratio (or): 1.02 · 95% CI 0.64 to 1.63P-value of treatment comparison at Week 26 is from repeated generalized linear mixed model (GLM model).
SecondaryChange From Baseline in Homeostasis Model Assessment 2 Steady-state Beta (β)- Cell Function (HOMA2-%B) at 26 Weeks

The homeostatic model assessment (HOMA) quantifies insulin resistance and beta-cell function. HOMA2-%B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady-state beta cell function (%B) as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100%. LS means of the HOMA2-%B change from baseline to primary endpoint at Week 26 was adjusted by fixed effects of treatment, country, baseline HbA1c strata, and baseline HOMA2-%B value as covariate, via an ANCOVA analysis using LOCF.

Time frame:
Baseline, Up to 26 Weeks
Reported as:
Least squares mean · percentage of HOMA2-%B
Change From Baseline in Homeostasis Model Assessment 2 Steady-state Beta (β)- Cell Function (HOMA2-%B) at 26 Weeks
percentage of HOMA2-%B1.5 mg LY21892651.8 mg Liraglutide
Change From Baseline in Homeostasis Model Assessment 2 Steady-state Beta (β)- Cell Function (HOMA2-%B) at 26 Weeks37.03 ± 2.2635.59 ± 2.27
Statistical analysis
  • 1.5 mg LY2189265 vs 1.8 mg Liraglutide · ANCOVA · p = 0.608 · Ls mean difference: 1.43 · 95% CI -4.06 to 6.92No adjustment for multiplicity.
SecondaryNumber of Participants With Reported and Adjudicated Cardiovascular Events

Deaths and nonfatal cardiovascular (CV) adverse events (AEs) were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal CV AEs to be adjudicated include myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. The number of participants with reported CV events, number of participants with nonfatal CV events confirmed by adjudication, and number of deaths confirmed by adjudication are summarized cumulatively at 26 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline up to 26 Weeks
Reported as:
Number · participants
Number of Participants With Reported and Adjudicated Cardiovascular Events
participants1.5 mg LY21892651.8 mg Liraglutide
Any reported CV events03
Any adjudicated nonfatal CV events01
Any confirmed adjudicated deaths00
SecondaryChange From Baseline in Electrocardiogram (ECG) Parameters, Heart Rate (HR) at 26 Weeks

ECG HR was measured. LS means of change from baseline were analyzed using ANCOVA with HbA1c strata, country, and treatment as fixed effects and baseline HR as a covariate.

Time frame:
Baseline, Up to 26 Weeks
Reported as:
Least squares mean · beats per minute (bpm)
Change From Baseline in Electrocardiogram (ECG) Parameters, Heart Rate (HR) at 26 Weeks
beats per minute (bpm)1.5 mg LY21892651.8 mg Liraglutide
Change From Baseline in Electrocardiogram (ECG) Parameters, Heart Rate (HR) at 26 Weeks1.9 ± 0.554.1 ± 0.54
SecondaryChange From Baseline in Electrocardiogram (ECG) Parameters PR and QTcF (Fridericia's) Intervals at 26 Weeks

The QT interval is a measure of the time between the start of the Q wave and the end of the T wave. QTcF is the measure of the time between the start of the Q wave and the end of the T wave adjusted using Fridericia's formula. PR is the interval between the P wave and the QRS complex. These parameters were calculated from electrocardiogram (ECG) data. LS means of change from baseline for the PR and QTcF intervals will be analyzed using the MMRM similar to MMRM model for primary outcome, using corresponding baseline and HbA1c strata. Only ECGs obtained at scheduled visits will be used in these summaries and analyses.

Time frame:
Baseline, 26 Weeks
Reported as:
Least squares mean · milliseconds (msec)
Change From Baseline in Electrocardiogram (ECG) Parameters PR and QTcF (Fridericia's) Intervals at 26 Weeks
milliseconds (msec)1.5 mg LY21892651.8 mg Liraglutide
PR interval (n=270, 278)3.8 ± 0.813.3 ± 0.80
QTcF interval (n=273, 284)0.39 ± 0.90-0.72 ± 0.89
SecondaryChange From Baseline in Heart Rate (HR) at 26 Weeks

Descriptive statistics for the actual measurements and LS means of change from baseline for HR (sitting) by treatment arm were analyzed using the MMRM model with treatment, country, visit, and treatment-by-visit interaction as fixed effects, baseline rate as a covariate, and participant as a random effect.

Time frame:
Baseline, 26 Weeks
Reported as:
Least squares mean · bpm
Change From Baseline in Heart Rate (HR) at 26 Weeks
bpm1.5 mg LY21892651.8 mg Liraglutide
Change From Baseline in Heart Rate (HR) at 26 Weeks2.37 ± 0.43.12 ± 0.4
SecondaryChange From Baseline in Blood Pressure (BP) at 26 Weeks

Descriptive statistics for the actual measurements and change from baseline for sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured. LS means of change from baseline were calculated using MMRM with treatment, country, visit, and treatment-by-visit interaction as fixed effects, baseline BP as a covariate, and participant as a random effect.

Time frame:
Baseline, 26 Weeks
Reported as:
Least squares mean · milliliters of mercury (mmHg)
Change From Baseline in Blood Pressure (BP) at 26 Weeks
milliliters of mercury (mmHg)1.5 mg LY21892651.8 mg Liraglutide
Sitting DBP-0.22 ± 0.4-0.31 ± 0.4
Sitting SBP-3.36 ± 0.7-2.82 ± 0.7
SecondaryNumber of Participants With Adjudicated Acute Pancreatitis Events

The number of participants with events of pancreatitis confirmed by adjudication were summarized cumulatively at 26 weeks (including a 30-day follow up). Pancreatitis events were adjudicated by a committee of physicians external to the Sponsor. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline up to 30 Weeks
Reported as:
Number · participants
Number of Participants With Adjudicated Acute Pancreatitis Events
participants1.5 mg LY21892651.8 mg Liraglutide
Number of Participants With Adjudicated Acute Pancreatitis Events00
SecondaryChange From Baseline in Calcitonin at 26 Weeks

A summary of participants having changes in calcitonin values from baseline to primary endpoint of 26 weeks is presented.

Time frame:
Baseline, Up to 26 Weeks
Reported as:
Median · picograms/milliliter (pcg/mL)
Change From Baseline in Calcitonin at 26 Weeks
picograms/milliliter (pcg/mL)1.5 mg LY21892651.8 mg Liraglutide
Change From Baseline in Calcitonin at 26 Weeks0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)
SecondaryChange From Baseline in Lipase at 26 Weeks

A summary of participants having changes in lipase evaluation from baseline to primary endpoint of 26 weeks is presented.

Time frame:
Baseline, Up to 26 Weeks
Reported as:
Median · units/liter (U/L)
Change From Baseline in Lipase at 26 Weeks
units/liter (U/L)1.5 mg LY21892651.8 mg Liraglutide
Change From Baseline in Lipase at 26 Weeks7.0 (0.5 to 17.5)11.0 (2.0 to 23.0)
SecondaryChange From Baseline in Amylase at 26 Weeks

A summary of participants having changes in amylase evaluation from baseline to primary endpoint of 26 weeks is presented.

Time frame:
Baseline, Up to 26 Weeks
Reported as:
Median · U/L
Change From Baseline in Amylase at 26 Weeks
U/L1.5 mg LY21892651.8 mg Liraglutide
Change From Baseline in Amylase at 26 Weeks7.0 (0.0 to 14.0)6.0 (0.0 to 13.0)
SecondaryPercentage of Participants With Self-Reported Hypoglycemia Events

Hypoglycemic events (HE) were classified as severe (episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (any time a participant felt that he/she was experiencing symptoms and/or signs associated with hypoglycemia and had a plasma glucose \[PG\] concentration of ≤70 mg/dL), asymptomatic (events not accompanied by typical symptoms of hypoglycemia but with a measured PG of ≤ 70 mg/dL), nocturnal (events that occurred between bedtime and waking), or probable symptomatic (events during which symptoms of hypoglycemia were not accompanied by a PG determination but that was presumably caused by a PG of ≤70 mg/dL). A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 26 Weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Self-Reported Hypoglycemia Events
percentage of participants1.5 mg LY21892651.8 mg Liraglutide
Documented symptomatic HE2.72.7
Asymptomatic HE6.73.3
Severe HE0.00.0
Nocturnal HE1.32.0
Probable symptomatic HE1.01.0
SecondaryPercentage of Participants Requiring Additional Intervention for Severe, Persistent Hyperglycemia

An additional intervention (rescue therapy) was defined as any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation.

Time frame:
Baseline through 26 Weeks
Reported as:
Number · percentage of participants
Percentage of Participants Requiring Additional Intervention for Severe, Persistent Hyperglycemia
percentage of participants1.5 mg LY21892651.8 mg Liraglutide
Percentage of Participants Requiring Additional Intervention for Severe, Persistent Hyperglycemia0.31.0
SecondaryRate of Hypoglycemic Events Adjusted Per 30 Days

HE were classified as severe (episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (any time a participant felt that he/she was experiencing symptoms and/or signs associated with hypoglycemia and had a PG concentration of ≤70 mg/dL), asymptomatic (events not accompanied by typical symptoms of hypoglycemia but with a measured PG of ≤ 70 mg/dL), nocturnal (events that occurred between bedtime and waking), or probable symptomatic (events during which symptoms of hypoglycemia were not accompanied by a PG determination but that was presumably caused by a PG of ≤70 mg/dL). The hypoglycemia rate per 30 days was calculated by the number of hypoglycemia events within the period/number of days participant at risk within the period\*30 days. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 26 Weeks
Reported as:
Mean · number of events/participant/30 days
Rate of Hypoglycemic Events Adjusted Per 30 Days
number of events/participant/30 days1.5 mg LY21892651.8 mg Liraglutide
Total HE0.03 ± 0.120.04 ± 0.25
Documented symptomatic HE0.01 ± 0.080.02 ± 0.17
Asymptomatic HE0.02 ± 0.070.01 ± 0.08
Severe HE0.00 ± 0.000.00 ± 0.00
Nocturnal HE0.01 ± 0.050.01 ± 0.10
Probable symptomatic HE0.00 ± 0.020.01 ± 1.12
SecondaryTime to Initiation of Additional Intervention for Severe, Persistent Hyperglycemia

An additional intervention (rescue therapy) was defined as any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation. Participants who had no rescue therapy within specified study period were considered as censored observations at the last available contact date up to specified study period.

Time frame:
Baseline through 26 Weeks
Reported as:
Median · weeks
Time to Initiation of Additional Intervention for Severe, Persistent Hyperglycemia
weeks1.5 mg LY21892651.8 mg Liraglutide
Time to Initiation of Additional Intervention for Severe, Persistent HyperglycemiaNA (0.975 to 1.000)NA (0.966 to 0.996)
SecondaryNumber of Participants With Allergic or Hypersensitivity Reactions

Allergic and hypersensitivity reactions that were considered possibly related to study drug by the investigator are presented. Serious and all other non-serious adverse events regardless of causality are summarized in the Reported Adverse Events module.

Time frame:
Baseline through 26 Weeks
Reported as:
Number · participants
Number of Participants With Allergic or Hypersensitivity Reactions
participants1.5 mg LY21892651.8 mg Liraglutide
Number of Participants With Allergic or Hypersensitivity Reactions15
SecondaryNumber of Participants With Treatment Emergent LY2189265 Antibodies up to 26 Weeks and 4 Weeks After Last Dose

LY2189265 (dulaglutide) anti-drug antibodies (ADA) were assessed at baseline, 26 weeks, and at the safety follow-up visit 4 weeks after study drug discontinuation in dulaglutide-treated participants. A participant was considered to have treatment emergent LY2189265 ADA if the participant had at least 1 titer that was treatment-emergent relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement. The number of participants with treatment-emergent LY2189265 ADA from postbaseline to follow up were summarized.

Time frame:
Baseline up to 4 Weeks Post Last Dose of Study Drug
Reported as:
Number · participants
Number of Participants With Treatment Emergent LY2189265 Antibodies up to 26 Weeks and 4 Weeks After Last Dose
participants1.5 mg LY2189265
Number of Participants With Treatment Emergent LY2189265 Antibodies up to 26 Weeks and 4 Weeks After Last Dose3
SecondaryPercent Change From Baseline in Lipid Parameters at 26 Weeks

A summary of percent change in lipid parameters (total cholesterol, high-density lipoprotein cholesterol \[HDL-C\], low density lipoprotein cholesterol \[LDL-C\], very low-density lipoprotein cholesterol \[VLDL\], and triglycerides) from baseline to primary endpoint of 26 weeks is presented. LS means of the lipid parameter from baseline to primary endpoint at Week 26 were adjusted by fixed effects of treatment, country, baseline HbA1c strata, and lipid parameter baseline as covariates, via ANCOVA with LOCF.

Time frame:
Baseline, Up to 26 Weeks
Reported as:
Least squares mean · percent
Percent Change From Baseline in Lipid Parameters at 26 Weeks
percentLY2189265Liraglutide
Total cholesterol (n=286, 284)-1.64 ± 1.180.67 ± 1.18
HDL-C (n=286, 284)6.21 ± 1.026.46 ± 1.02
LDL-C (n=276, 276)-1.09 ± 2.173.20 ± 2.15
VLDL (n=276, 276)1.56 ± 2.632.92 ± 2.60
Triglycerides (n=286, 284)0.59 ± 2.761.35 ± 2.76

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1.5 mg LY2189265—5/299 (1.7%)185/299 (61.9%)
1.8 mg Liraglutide—11/300 (3.7%)186/300 (62%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
Event1.5 mg LY21892651.8 mg Liraglutide
CholelithiasisHepatobiliary disorders1/2990/300
BronchopneumoniaInfections and infestations1/2990/300
Ankle fractureInjury, poisoning and procedural complications1/2990/300
FallInjury, poisoning and procedural complications1/2990/300
MeningiomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2990/300
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2990/300
EpilepsyNervous system disorders1/2990/300
SchizophreniaPsychiatric disorders1/2990/300
Angina pectorisCardiac disorders0/2991/300
TachyarrhythmiaCardiac disorders0/2991/300
Most frequent other events
Most frequent other events
Event1.5 mg LY21892651.8 mg Liraglutide
NauseaGastrointestinal disorders61/29954/300
DiarrhoeaGastrointestinal disorders36/29936/300
VomitingGastrointestinal disorders21/29925/300
HeadacheNervous system disorders22/29925/300
DyspepsiaGastrointestinal disorders24/29918/300
NasopharyngitisInfections and infestations23/29921/300
Decreased appetiteMetabolism and nutrition disorders16/29920/300
ConstipationGastrointestinal disorders11/29917/300
Back painMusculoskeletal and connective tissue disorders11/29915/300

Baseline characteristics

Participants who were randomized and received at least 1 dose of LY2189265 or Liraglutide

Age, Continuous
Age, Continuous(years)LY2189265LiraglutideTotal
Mean56.49 ± 9.3456.81 ± 9.9156.65 ± 9.63
Sex: Female, Male
Sex: Female, Male(Participants)LY2189265LiraglutideTotal
Female161151312
Male138149287
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)LY2189265LiraglutideTotal
Hispanic or Latino7572147
Not Hispanic or Latino221223444
Unknown or Not Reported358
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LY2189265LiraglutideTotal
American Indian or Alaska Native202343
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American211637
White256259515
More than one race123
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)LY2189265LiraglutideTotal
United States9797194
Czech Republic272855
Hungary211940
Mexico202141
Slovakia202242
Puerto Rico347
Poland394281
Spain242448
Romania201737
Germany282654
Body Weight
Body Weight(kilograms (kg))LY2189265LiraglutideTotal
Mean93.82 ± 18.2394.35 ± 18.9694.09 ± 18.58
Body Mass Index (BMI)
Body Mass Index (BMI)(kilograms per meter squared (kg/m^2))LY2189265LiraglutideTotal
Mean33.50 ± 5.0733.62 ± 5.1633.56 ± 5.11
Glycosylated hemoglobin (HbA1c)
Glycosylated hemoglobin (HbA1c)(percentage of glycosylated hemoglobin)LY2189265LiraglutideTotal
Mean8.06 ± 0.818.05 ± 0.798.05 ± 0.80

1 further baseline measures are reported on the registry.

08

Study locations

57 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Phoenix, Arizona 85027, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chino, California 91710, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fresno, California 93720, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Los Angeles, California 90057, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Spring Valley, California 91978, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fort Lauderdale, Florida 33316, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Miami, Florida 33175, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Oviedo, Florida 32765, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Topeka, Kansas 66606, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Louisville, Kentucky 40218, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shreveport, Louisiana 71101, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Royal Oak, Michigan 48073, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Las Vegas, Nevada 89119, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Perrysburg, Ohio 43551, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kingsport, Tennessee 37660, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dallas, Texas 75230, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hurst, Texas 76054, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Antonio, Texas 78228, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Prague, 181 00, Czech Republic
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dresden, 01307, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hohenmölsen, 06679, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lingen, 49808, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mainz, 55116, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Neunkirchen, 66539, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    St. Ingbert-Oberwürzbach, 66386, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sulzbach, 92237, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Budapest, H-1139, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Debrecen, 4043, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dombovar, 7200, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Szekesfehervar, 8000, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Monterrey, 64620, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bialystok, 15-445, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gdansk, 80-546, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kamieniec Zabkowicki, 57-230, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lodz, 90-242, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Poznan, 61-853, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ruda Slaska, 41-709, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Szczecin, 70-506, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tychy, 43-100, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wroclaw, 50-306, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hato Rey, 00917, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rio Grande, 00745, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bucharest, 020045, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Galati, 800098, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ploiesti, 100342, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sibiu, 550371, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kosice, 04012, Slovakia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Malacky, 90101, Slovakia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nitra, 94901, Slovakia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nove Mesto Nad Vahom, 91501, Slovakia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Alcira, 46600, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Alicante, 03114, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Barcelona, 08022, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Centelles, 08540, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Málaga, 29006, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Palma De Mallorca, 07014, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Petrer, 03610, Spain
09

References and documents

Publications

  • Boustani MA, Pittman I 4th, Yu M, Thieu VT, Varnado OJ, Juneja R. Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged >/=65 and <65 years. Diabetes Obes Metab. 2016 Aug;18(8):820-8. doi: 10.1111/dom.12687. Epub 2016 Jun 7. PubMed 27161178 ↗
  • Yu M, Van Brunt K, Varnado OJ, Boye KS. Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes Obes Metab. 2016 Apr;18(4):419-24. doi: 10.1111/dom.12624. Epub 2016 Feb 4. PubMed 26691396 ↗
  • Dungan KM, Povedano ST, Forst T, Gonzalez JG, Atisso C, Sealls W, Fahrbach JL. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014 Oct 11;384(9951):1349-57. doi: 10.1016/S0140-6736(14)60976-4. Epub 2014 Jul 10. Erratum In: Lancet. 2014 Oct 11:384(9951):1348. PubMed 25018121 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2012, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 11 months after primary completion. A results delay was requested in Jan 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2012
First posted
Jun 20, 2012
Start
Jun 2012
Primary completionActual
Nov 2013
CompletionActual
Nov 2013
Results delay requested
Jan 7, 2014
Results first posted
Oct 9, 2014
Last update
Oct 9, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01624259
Responsible party
Sponsor
First posted
Jun 20, 2012
Start date
Jun 2012
Primary completion
Nov 2013
Completion
Nov 2013
Results posted
Oct 9, 2014
Last update
Oct 9, 2014

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM-5 PM Eastern time (UTC/GMT-5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dulaglutide

Start the discussion